Answers are grounded in this paper and cite their sources.
This conceptual paper introduces Revision of the Approval Standard for an Unchanged Result, a mechanism by which a result loses approval when the rule used to assess it changes, even though the result and its intended use remain the same. The paper distinguishes the date a rule is adopted, the date it becomes applicable to existing results, and the decision that applies it in a particular case. The earlier standard matters because a later refusal can also uncover a requirement the result failed to meet all along. The documented case is Lutrexin. Its U.S. drug application took effect in 1953 under a safety standard, although the evidence for its claimed effectiveness was already considered weak. In 1962, Congress added a requirement for substantial evidence of effectiveness. For existing approvals covering unchanged labeled uses, withdrawal on that ground was generally deferred until October 1964. An initial withdrawal in 1971 was reversed. The FDA’s final withdrawal took effect on April 15, 1976, for insufficient evidence of effectiveness. The approval history follows the same application for the same labeled uses. The 2021 industry standard for labeling Japanese whisky provides a contrast. Association members could continue certain existing uses of wording and imagery through March 31, 2024. At the announcement, Nikka reported that some of its whiskies fell outside the definition and that its existing labels were unaffected. Establishing that a particular whisky lost the designation would require its labeling history. Part of the Assessment and Attribution series within On Human Modeling, the paper places the mechanism alongside Lon Fuller’s account of retroactive law. In an AI evaluation, a reviewer might approve a summary for factual accuracy and later assess the identical text for the same use under a revised rule requiring page references. A refusal for missing references would show when the new requirement changed that summary’s standing.
No takes yet. Share an insight, caveat, or question.
Alexandra Cary (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: